Your browser doesn't support javascript.
loading
Sarcopenia and Cardiovascular Diseases.
Damluji, Abdulla A; Alfaraidhy, Maha; AlHajri, Noora; Rohant, Namit N; Kumar, Manish; Al Malouf, Christina; Bahrainy, Samira; Ji Kwak, Min; Batchelor, Wayne B; Forman, Daniel E; Rich, Michael W; Kirkpatrick, James; Krishnaswami, Ashok; Alexander, Karen P; Gerstenblith, Gary; Cawthon, Peggy; deFilippi, Christopher R; Goyal, Parag.
Afiliação
  • Damluji AA; Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA (A.A.D., W.B.B., C.R.D.).
  • Alfaraidhy M; Johns Hopkins University School of Medicine, Baltimore, MD (A.A.D., M.A., G.G.).
  • AlHajri N; Johns Hopkins University School of Medicine, Baltimore, MD (A.A.D., M.A., G.G.).
  • Rohant NN; Cleveland Clinic, Abu Dhabi, United Arab Emirates (N.A.).
  • Kumar M; University of Arizona, Tucson (N.N.R., P.G.).
  • Al Malouf C; University of Connecticut, Hartford (M.K.).
  • Bahrainy S; Weill Cornell Medicine, New York, NY (C.A.M.).
  • Ji Kwak M; University of Washington, Seattle (S.B., J.K.).
  • Batchelor WB; University of Texas, Houston (M.J.K.).
  • Forman DE; Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA (A.A.D., W.B.B., C.R.D.).
  • Rich MW; University of Pittsburgh and the Pittsburgh Geriatric Research Education and Clinical Center, PA (D.E.F.).
  • Kirkpatrick J; Washington University, St Louis, MO (M.W.R.).
  • Krishnaswami A; University of Washington, Seattle (S.B., J.K.).
  • Alexander KP; Kaiser Permanente, San Jose, CA (A.K.).
  • Gerstenblith G; Duke Clinical Research Institute, Duke University, Durham, NC (K.P.A.).
  • Cawthon P; Johns Hopkins University School of Medicine, Baltimore, MD (A.A.D., M.A., G.G.).
  • deFilippi CR; University of California San Francisco (P.C.).
  • Goyal P; Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA (A.A.D., W.B.B., C.R.D.).
Circulation ; 147(20): 1534-1553, 2023 05 16.
Article em En | MEDLINE | ID: mdl-37186680
ABSTRACT
Sarcopenia is the loss of muscle strength, mass, and function, which is often exacerbated by chronic comorbidities including cardiovascular diseases, chronic kidney disease, and cancer. Sarcopenia is associated with faster progression of cardiovascular diseases and higher risk of mortality, falls, and reduced quality of life, particularly among older adults. Although the pathophysiologic mechanisms are complex, the broad underlying cause of sarcopenia includes an imbalance between anabolic and catabolic muscle homeostasis with or without neuronal degeneration. The intrinsic molecular mechanisms of aging, chronic illness, malnutrition, and immobility are associated with the development of sarcopenia. Screening and testing for sarcopenia may be particularly important among those with chronic disease states. Early recognition of sarcopenia is important because it can provide an opportunity for interventions to reverse or delay the progression of muscle disorder, which may ultimately impact cardiovascular outcomes. Relying on body mass index is not useful for screening because many patients will have sarcopenic obesity, a particularly important phenotype among older cardiac patients. In this review, we aimed to (1) provide a definition of sarcopenia within the context of muscle wasting disorders; (2) summarize the associations between sarcopenia and different cardiovascular diseases; (3) highlight an approach for a diagnostic evaluation; (4) discuss management strategies for sarcopenia; and (5) outline key gaps in knowledge with implications for the future of the field.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Sarcopenia Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Sarcopenia Idioma: En Ano de publicação: 2023 Tipo de documento: Article